These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25202035)

  • 1. The power of genes: a case of unusually severe systemic toxicity after localized hepatic chemoembolization with irinotecan-eluted microspheres for metastatic colon cancer.
    Cruz JE; Saksena R; Jabbour SK; Nosher JL; Hermes-DeSantis E; Moss RA
    Ann Pharmacother; 2014 Dec; 48(12):1646-50. PubMed ID: 25202035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer.
    Narayanan G; Barbery K; Suthar R; Guerrero G; Arora G
    Anticancer Res; 2013 May; 33(5):2077-83. PubMed ID: 23645758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases.
    Bhutiani N; Akinwande O; Martin RC
    World J Surg; 2016 May; 40(5):1178-90. PubMed ID: 26711640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of TACE With Irinotecan-loaded Drug-eluting Beads (DEBIRI) in Patients With Liver Metastases from Unresectable Colorectal Cancer.
    Ishikawa T; Imai M; Sato R; Jimbo R; Kobayashi Y; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
    Anticancer Res; 2023 Aug; 43(8):3647-3651. PubMed ID: 37500124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review.
    Richardson AJ; Laurence JM; Lam VW
    J Vasc Interv Radiol; 2013 Aug; 24(8):1209-17. PubMed ID: 23885916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.
    Onoue M; Terada T; Kobayashi M; Katsura T; Matsumoto S; Yanagihara K; Nishimura T; Kanai M; Teramukai S; Shimizu A; Fukushima M; Inui K
    Int J Clin Oncol; 2009 Apr; 14(2):136-42. PubMed ID: 19390945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis.
    Zhang X; Yin JF; Zhang J; Kong SJ; Zhang HY; Chen XM
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):135-149. PubMed ID: 28585035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial.
    Pernot S; Artru P; Mithieux F; Marsot J; Watkin E; Pellerin O; Lledo G; Chalabreysse P; Desramé J; Taieb J
    Clin Res Hepatol Gastroenterol; 2015 Dec; 39(6):e73-7. PubMed ID: 26141343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoembolization with drug eluting beads preloaded with irinotecan (DEBIRI) vs doxorubicin (DEBDOX) as a second line treatment for liver metastases from cholangiocarcinoma: a preliminary study.
    Venturini M; Sallemi C; Agostini G; Marra P; Cereda S; Reni M; Aldrighetti L; De Cobelli F; Del Maschio A
    Br J Radiol; 2016 Nov; 89(1067):20160247. PubMed ID: 27558984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrence of UGT1A polymorphism and end-stage renal disease leads to severe toxicities of irinotecan in a patient with metastatic colon cancer.
    Huang SH; Chao Y; Wu YY; Luo JC; Kao CH; Yen SH; Li CP
    Tumori; 2011; 97(2):243-7. PubMed ID: 21617725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
    Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
    Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.
    Xu JM; Wang Y; Ge FJ; Lin L; Liu ZY; Sharma MR
    World J Gastroenterol; 2013 Jun; 19(24):3899-903. PubMed ID: 23840132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.
    Kuhlmann JB; Euringer W; Spangenberg HC; Breidert M; Blum HE; Harder J; Fischer R
    Eur J Gastroenterol Hepatol; 2012 Apr; 24(4):437-43. PubMed ID: 22261548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors for overall survival and safety of trans-arterial chemoembolization (TACE) with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with colorectal liver metastases.
    Sljivic M; Sever M; Ocvirk J; Mesti T; Brecelj E; Popovic P
    Radiol Oncol; 2024 Jun; 58(2):214-220. PubMed ID: 38553252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.
    Hirose K; Yamashita K; Takada H; Kaneda N; Fukami K; Maruo E; Kitamura M; Hasegawa J; Maeda Y
    Int J Clin Oncol; 2014 Apr; 19(2):397-402. PubMed ID: 23605141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transarterial Chemoembolization of Liver Metastases from Uveal Melanoma Using Irinotecan-Loaded Beads: Treatment Response and Complications.
    Carling U; Dorenberg EJ; Haugvik SP; Eide NA; Berntzen DT; Edwin B; Dueland S; Røsok B
    Cardiovasc Intervent Radiol; 2015 Dec; 38(6):1532-41. PubMed ID: 25832764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARAGON II - A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer.
    Jones RP; Malik HZ; Fenwick SW; Terlizzo M; O'Grady E; Stremitzer S; Gruenberger T; Rees M; Plant G; Figueras J; Albiol M; Adam R; Awad S; Poston GJ
    Eur J Surg Oncol; 2016 Dec; 42(12):1866-1872. PubMed ID: 27561844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of the Clinical Evidence for the Use of DEBIRI in the Treatment of Colorectal Metastatic Disease.
    Young S; D'Souza D; Flanagan S; Golzarian J
    Cardiovasc Intervent Radiol; 2017 Apr; 40(4):496-501. PubMed ID: 28004168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
    Gao J; Zhou J; Li Y; Lu M; Jia R; Shen L
    Med Oncol; 2013; 30(3):604. PubMed ID: 23686699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.
    Biason P; Masier S; Toffoli G
    J Chemother; 2008 Apr; 20(2):158-65. PubMed ID: 18467239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.